Research programme: anabolic bone therapeutics - Acceleron

Drug Profile

Research programme: anabolic bone therapeutics - Acceleron

Alternative Names: ACE-05X; ACE-661

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acceleron Pharma
  • Class Proteins
  • Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bone resorption

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-resorption in USA
  • 21 Feb 2008 Acceleron Pharma and Celgene Corporation enter into an option agreement for certain discovery stage bone loss programmes
  • 21 Feb 2008 Early research in Bone regeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top